drugset / Trial / NCT06194448
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent CRT and maintenance osimertinib in adult patients with Stage III, unresectable NSCLC with common EGFR mutations (exon 19 deletion or L858R).
Timeline
- Start
- 2024-04-21
- Primary completion
- 2026-07-07
- Completion
- 2027-07-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Osimertinib | Small molecule | 80 mg | — |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | — |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | — |